Advances in Perinatal Stem Cells Research: a Precious Cell Source for Clinical Applications

Abbaspanah, Bahareh; Momeni, Maryam; Ebrahimi, Marzieh; Mousavi, Seyed Hadi

doi:10.2217/rme-2018-0019

Cited by 33 publications

(33 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MSCs produce exosomes that contain growth factors, mRNA, microRNA and mitochondrial companents. This content ensures that the exosomes are long-acting [42][43][44].. MSCs are nonhematopoietic multipotent stromal cells that can be isolated from different sources, including bone marrow, adipose tissue, umbilical cord tissue, cord blood, placenta, dental pulp and amniotic fluid [12,45,46]. Umbilical cord Wharton's jelly derived mesenchymal stem cells (WJ-MSCs) are superior to other cell types in retinal degeneration in terms of how easily we can obtain these cells, as well as their tissue compatibility, rapid proliferation, long-term efficacy in the transplanted tissue, high paracrine effect, immunomodulation effect, non-tumoral side effect, and because these cells have similar features as the retinal pigment epithelium [13][14][15][16][17][18][19][20][21].…”

Section: Discussionmentioning

confidence: 99%

“…WJ-MSCs also undergo less nuclear and mitochondrial mutations compared to MSCs collected from adult tissues. WJ-MSCs do not stimulate T-cell proliferation because they do not express MHC class II [45,46].. WJ-MSCs have an effect on activated macrophages, reducing the secretion of inflammatory factors [12][13][14][15][16][17][18][19][20][21]. MSCs secrete factors that support cell survival and regulate adjacent cells in damaged tissue; hence, they can rescue the damaged naive nature of MSCs derived from an umbilical cord.…”

Section: Discussionmentioning

confidence: 99%

“…Growth factors obtained from PRP last for 4-6 months and require booster injections. Adipose MSCs can proliferate in tissues 5 times without karyotype changes [12,45,46] and WJ-MSCs can proliferate 25-300 times without karyotype changes [12-21, 45, 56]. This means that the paracrine-trophic effects of WJ-MSCs may persist for 3-7 years in the tissue where they are transplanted allogeneically.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results

Özmert

Arslan

2020

Stem Cell Res Ther

View full text Add to dashboard Cite

Purpose: The aim of this study is to determine if umbilical cord Wharton's jelly derived mesenchymal stem cells implanted in sub-tenon space have beneficial effects on visual functions in retinitis pigmentosa patients by reactivating the degenerated photoreceptors in dormant phase. Material and methods:This prospective, open-label, phase-3 clinical trial was conducted between April of 2019 and October of 2019 at Ankara University Faculty of Medicine, Department of Ophthalmology. 32 RP patients (34 eyes) were included in the study. The patients were followed for 6 months after the Wharton's jelly derived mesenchymal stem cell administration, and evaluated with consecutive examinations. All patients underwent a complete routine ophthalmic examination, and best corrected visual acuity, optical coherens tomography angiography, visual field, multifocal and full-field electroretinography were performed. The quantitative results were obtained from a comparison of the pre-injection and final examination (6th month) values.Results: The mean best corrected visual acuity was 70.5 letters prior to Wharton's jelly derived mesenchymal stem cell application and 80.6 letters at the 6th month (p = 0.01). The mean visual field median deviation value was 27.3 dB before the treatment and 24.7 dB at the 6th month (p = 0.01). The mean outer retinal thickness was 100.3 μm before the treatment and 119.1 μm at 6th month (p = 0.01). In the multifocal electroretinography results, P1 amplitudes improved in ring1 from 24.8 to 39.8 nv/deg2 (p = 0.01), in ring2 from 6.8 to 13.6 nv/deg2 (p = 0.01), and in ring3 from 3.1 to 5.7 nv/deg2 (p = 0.02). P1 implicit times improved in ring1 from 44.2 to 32.4 ms (p = 0.01), in ring2 from 45.2 to 33.2 ms (p = 0.02), and in ring3 from 41.9 to 32.4 ms (p = 0.01). The mean amplitude improved in 16 Tds from 2.4 to 5.0 nv/deg2 (p = 0.01) and in 32 Tds from 2.4 to 4.8 nv/deg2 (p = 0.01) in the full-field flicker electroretinography results. Full field flicker electroretinography mean implicit time also improved in 16 Tds from 43.3 to 37.9 ms (p = 0.01). No ocular or systemic adverse events related to the two types of surgical methods and/or Wharton's jelly derived mesenchymal stem cells itself were observed during the follow-up period.Conclusion: RP is a genetic disorder that can result in blindness with outer retinal degeneration. Regardless of the type of genetic mutation, sub-tenon Wharton's jelly derived mesenchymal stem cell administration appears to be an effective and safe option. There are no serious adverse events or ophthalmic / systemic side effects for 6 months follow-up. Although the long-term adverse effects are still unknown, as an extraocular approach, subtenon implantation of the stem cells seems to be a reasonable way to avoid the devastating side effects of intravitreal/submacular injection. Further studies that include long-term follow-up are needed to determine the duration of efficacy and the frequency of application.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results

Özmert

Arslan

2020

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…Several types of stem cells have been subjected to clinical trials ( 106 ). Stem cells derived from the human placenta have been reported to be in clinical trials for a variety of therapeutic applications ( 107 ). In a single-center, non-randomized, intravenous dose-escalation phase Ib trial, patients with idiopathic pulmonary fibrosis received intravenous administration of placental MSCs from unrelated donors.…”

Section: Clinical Trialsmentioning

confidence: 99%

Human Amniotic Mesenchymal Stem Cells Promote Endogenous Bone Regeneration

et al. 2020

View full text Add to dashboard Cite

Bone regeneration has become a research hotspot and therapeutic target in the field of bone and joint medicine. Stem cell-based therapy aims to promote endogenous regeneration and improves therapeutic effects and side-effects of traditional reconstruction of significant bone defects and disorders. Human amniotic mesenchymal stem cells (hAMSCs) are seed cells with superior paracrine functions on immune-regulation, anti-inflammation, and vascularized tissue regeneration. The present review summarized the source and characteristics of hAMSCs and analyzed their roles in tissue regeneration. Next, the therapeutic effects and mechanisms of hAMSCs in promoting bone regeneration of joint diseases and bone defects. Finally, the clinical application of hAMSCs from current clinical trials was analyzed. Although more studies are needed to confirm that hAMSC-based therapy to treat bone diseases, the clinical application prospect of the approach is worth investigating.

show abstract

“…MSCs are a class of cells originating in the mesoderm, including bone marrow MSCs and adipose MSCs, etc. Human umbilical cord MSCs (hucMSCs) are one of the important sources of MSCs [4,5], and they have strong proliferation and low immunity. Studies have reported that MSCs have homing effect on tumours such as glioma and ovarian cancer, and have anti-tumour effect on blood cancer and breast cancer [6,7].…”

Section: Introductionmentioning

confidence: 99%

Human umbilical cord mesenchymal stem cells suppress lung cancer via TLR4/NF-κB signalling pathway

Pan

Cai

et al. 2020

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

The present study investigated the inhibitory effect of human umbilical cord mesenchymal stem cells (hucMSCs) on the growth of lung cancer in mice and its relationship with the TLR4/NF-jB signalling pathway. A mouse model of Lewis lung cancer was constructed by inoculating mice with Lewis lung cancer cell suspension under the axilla. Twenty mice were randomly and evenly divided into experimental group and control group. The experimental group received a caudal vein injection of 1 Â 10 6 hucMSCs each week for two consecutive weeks, and the control group, an equal amount of saline at the same time. Two weeks after treatment with hucMSCs, the mice were sacrificed and the tumour volume and tumour weight were recorded. Enzyme-linked immunosorbent assay was used to determine the IL-1, IL-6 and TNF-a contents in lung cancer tissues; real-time polymerase chain reaction, to measure the level of mRNA; and Western blotting, to determine the protein expression. The results showed that injection of hucMSCs inhibited the growth of Lewis lung cancer tissues, reduced Lewis lung cancer tissue weight, enhanced thymus index, and suppressed inflammatory responses. hucMSCs inhibited the expression of inflammatory factors IL-1, IL-6 and TNF-a by activating TLR4/NF-jB signalling pathway, and facilitated the expression of Bax. Moreover, huMSCs induced the expression of apoptogenic factor Bax by activating TLR4/NF-jB signalling pathway, and inhibited the expression of antiapoptotic factor bcl-2. The present study demonstrates that hucMSCs reduce inflammatory responses by mediating TLR4/NF-jB signalling pathway, promote apoptosis of tumour cells, and inhibit tumour proliferation in mice with Lewis lung cancer. ARTICLE HISTORY

show abstract

Advances in Perinatal Stem Cells Research: a Precious Cell Source for Clinical Applications

Cited by 33 publications

References 133 publications

Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results

Management of retinitis pigmentosa by Wharton’s jelly derived mesenchymal stem cells: preliminary clinical results

Human Amniotic Mesenchymal Stem Cells Promote Endogenous Bone Regeneration

Human umbilical cord mesenchymal stem cells suppress lung cancer via TLR4/NF-κB signalling pathway

Contact Info

Product

Resources

About